Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other financing activities (2022 - 2024)

Verrica Pharmaceuticals has reported Other financing activities over the past 3 years, most recently at $163000.0 for Q3 2024.

  • Quarterly results put Other financing activities at $163000.0 for Q3 2024, up 167.21% from a year ago — trailing twelve months through Sep 2024 was $163000.0 (down 5.78% YoY), and the annual figure for FY2022 was $17000.0, changed.
  • Other financing activities for Q3 2024 was $163000.0 at Verrica Pharmaceuticals, up from -$173000.0 in the prior quarter.
  • Over the last five years, Other financing activities for VRCA hit a ceiling of $163000.0 in Q3 2024 and a floor of -$173000.0 in Q4 2023.
  • Median Other financing activities over the past 3 years was $61000.0 (2023), compared with a mean of $36000.0.
  • Peak annual rise in Other financing activities hit 167.21% in 2024, while the deepest fall reached 167.21% in 2024.
  • Verrica Pharmaceuticals' Other financing activities stood at $17000.0 in 2022, then crashed by 1117.65% to -$173000.0 in 2023, then soared by 194.22% to $163000.0 in 2024.
  • The last three reported values for Other financing activities were $163000.0 (Q3 2024), -$173000.0 (Q4 2023), and $61000.0 (Q3 2023) per Business Quant data.